Trial · NCT02550717
Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)
NCT02550717, Completed, Bayer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN). Trials, record NCT02550717. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02550717
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)
- NCT number
- NCT02550717
- Status
- Completed
- Enrollment
- 398,158 participants, actual
- Lead sponsor
- Bayer
- Conditions
- Secondary Prevention, Stroke, Ischemic Heart Disease, Coronary Heart Disease
- Interventions
- Acetylsalicylic Acid (Aspirin, BAYE4465), Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs
- First posted
- 2015-09-15
- Last updated
- 2018-10-24
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Intracranial bleeding among new users of low-dose Acetylsalicylic acid (ASA). | Up to 13 years | |
| Primary | Incidence of Upper gastrointestinal bleeding among new users of low-dose ASA. | Up to 13 years | |
| Primary | Incidence of Lower gastrointestinal bleeding among new users of low-dose ASA | Up to 13 years | |
| Primary | Time to Intracranial bleeding among new users of low-dose ASA | Up to 13 years | |
| Primary | Time to Upper gastrointestinal bleeding among new users of low-dose ASA | Up to 13 years | |
| Primary | Time to Lower gastrointestinal bleeding among new users of low-dose ASA | Up to 13 years | |
| Primary | Relative risk of Intracranial bleeding among new users of low dose ASA | Up to 13 years | Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed. |
| Primary | Relative risk of Upper gastrointestinal bleeding among new users of low-dose ASA | Up to 13 years | Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed. |
| Primary | Relative risk of Lower gastrointestinal bleeding among new users of low-dose ASA | Up to 13 years | Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed. |
| Secondary | Relative risk of Intracranial bleeding associated with use of other medications. | Up to 13 years | Relative risk is calculated as incident rate ratio produced by dividing the incidence rate of the outcome of interest in the exposed category by the incidence rate of the outcome of interest in the unexposed.To estimate relative risk in users of other medications such as clopidogrel,oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs), independently from use of low-dose ASA and concomitantly |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02550717
GET https://conductscience.org/api/trials/v1/NCT02550717/registered